EGFR and non-small cell lung carcinoma: This real-world performance compares favorably to clinical trial data for positive percent agreement (sensitivity) of ctDNA-based assays in the detection of EGFR mutations (droplet digital polymerase chain reaction (PCR), 51–81%; NGS, 50–86%) in the plasma of patients with EGFR-mutated NSCLC previously identified through tissue testing [15].